Prostate cancer can be slow to progress, frustrating the development of new therapies for patients with early, high-risk disease. New results from ICECaP (Intermediate Clinical Endpoints for Cancer of the Prostate), a PCF-supported initiative led by Dr. Christopher Sweeney, will cut the time required to assess new therapies for aggressive.
Investigator: Steve Y. Cho, MD – Assistant Professor, Johns Hopkins University Translation of [18F]DCFBC PET:A Novel Prostate Imaging Biomarker Positron Emission Tomography (PET) is a molecular imaging technique that can produce a 3-D image of human cancers. This system works by injecting a patient with a radionuclide tracer (a compound.
PCF-Department of Defense Prostate Cancer Clinical Trials Consortium (PCCTC) As part of its aggressive plan to fund and accelerate research—and to speed the results to patients worldwide—PCF has invested more than $45 million in a consortium of 13 leading cancer centers, featuring some of the world’s most respected prostate cancer clinical.
Clinical drug trials play a crucial role in moving new treatments to patients who need them most. Patients who participate in clinical trials provide an invaluable service both to treatment science and fellow patients. Use our tool to search for clinical trials that are currently open for enrollment.